Is losartan (an angiotensin II receptor blocker) nephrotoxic?

Losartan is NOT inherently nephrotoxic—it is actually renoprotective in most clinical contexts

Losartan is recommended as a first-line agent for kidney protection in patients with diabetes, hypertension, and albuminuria, where it slows progression of chronic kidney disease. 1 However, like all angiotensin II receptor blockers (ARBs), losartan can cause reversible changes in renal function under specific high-risk circumstances—this is a hemodynamic effect, not direct toxicity.

Understanding the Mechanism: Hemodynamic vs. Toxic Effects

Losartan works by blocking angiotensin II receptors, which dilates the efferent arteriole of the glomerulus. This reduces intraglomerular pressure and protects the kidney long-term, but can temporarily decrease glomerular filtration rate (GFR) in patients whose kidney function depends heavily on angiotensin II activity 2.

This is NOT nephrotoxicity—it's a predictable hemodynamic consequence that is:

• Usually reversible upon drug discontinuation
• Expected and often acceptable (up to 30% creatinine rise is tolerated) 1
• Different from direct cellular damage

High-Risk Situations Where Renal Function May Decline

1. Bilateral Renal Artery Stenosis or Stenosis in a Solitary Kidney

• Risk: Acute renal failure can occur because kidney perfusion depends entirely on angiotensin II-mediated efferent arteriolar constriction 3, 4, 5
• Action: Consider renal artery stenosis if creatinine rises >30% within 4 weeks 1

2. Volume Depletion or Hypotension

• Risk: Patients on high-dose diuretics, with heart failure, or who are volume-depleted may experience symptomatic hypotension and acute kidney injury 2
• Action: Correct volume status before initiating losartan 3, 4

3. Pre-existing Chronic Kidney Disease (CKD)

• Risk: Patients with CKD (especially GFR <30 mL/min) have 50-90% higher plasma concentrations of losartan and may experience greater creatinine increases 2
• Action: Monitor creatinine and potassium within 2-4 weeks of starting or dose changes 1
• Tolerance: Continue losartan unless creatinine rises >30% within 4 weeks 1

4. Concomitant Nephrotoxins

• Risk: NSAIDs, other diuretics, or dual RAS blockade (ACE inhibitor + ARB) increase risk of acute kidney injury and hyperkalemia 5, 1
• Action: Avoid combining losartan with ACE inhibitors or direct renin inhibitors—this is potentially harmful 5, 1, 6

Monitoring Protocol

Within 2-4 weeks of starting losartan or increasing dose 1:

• Check serum creatinine and potassium
• If creatinine rises <30%: Continue losartan and increase dose as tolerated
• If creatinine rises >30%:
  • Review for volume depletion, hypotension, NSAIDs, or renal artery stenosis
  • Correct reversible factors
  • Consider reducing dose or temporarily stopping losartan 1
• If hyperkalemia develops: Manage potassium medically (dietary restriction, diuretics, potassium binders) rather than immediately stopping losartan 1, 7

Evidence of Renoprotection (Not Toxicity)

The RENAAL trial demonstrated that losartan reduces the risk of doubling serum creatinine and progression to end-stage renal disease in diabetic nephropathy patients 8, 6. The KDIGO 2022 guidelines strongly recommend ARBs like losartan for patients with diabetes, CKD, and albuminuria specifically for kidney protection 1.

Special Populations

Pregnancy

• Contraindicated in 2nd and 3rd trimesters: Causes fetal renal dysfunction, oligohydramnios, and neonatal renal failure 2
• Discontinue immediately when pregnancy detected 3, 4, 5

Severe Renal Failure (GFR <15 mL/min)

• May reduce dose or discontinue to minimize uremic symptoms, but not because of direct toxicity 1

Hemodialysis

• Losartan is not removed by dialysis 2

Common Pitfalls to Avoid

1. Confusing hemodynamic creatinine rise with nephrotoxicity: A modest, stable creatinine increase is expected and acceptable—don't stop losartan prematurely
2. Dual RAS blockade: Never combine losartan with ACE inhibitors or direct renin inhibitors—this increases acute kidney injury and hyperkalemia without added benefit 5, 1
3. Ignoring volume status: Always assess and correct volume depletion before starting losartan
4. Stopping losartan for hyperkalemia without attempting medical management first: Use dietary potassium restriction, diuretics, or potassium binders before discontinuing 1, 7

Bottom Line

Losartan is renoprotective, not nephrotoxic. It may cause reversible hemodynamic changes in renal function in high-risk patients (bilateral renal artery stenosis, volume depletion, severe CKD), but these are predictable, manageable, and distinct from direct kidney damage. The drug should be continued in most patients with appropriate monitoring, as the long-term kidney and cardiovascular benefits far outweigh the risks 1, 6, 9.